Retinal Imaging Scientific Journals

High Impact List of Articles

• Iron deficiency anemia as a risk factor of childhood asthma Maghrib S AlKhateeb, Hassan M Khalil, Mezher M Kadhim, Jalil I Alezzi and Najdat Sh Mahmoud

  Research Article: Clinical Investigation

• Iron deficiency anemia as a risk factor of childhood asthma Maghrib S AlKhateeb, Hassan M Khalil, Mezher M Kadhim, Jalil I Alezzi and Najdat Sh Mahmoud

  Research Article: Clinical Investigation

• Iron deficiency anemia as a risk factor of childhood asthma Maghrib S AlKhateeb, Hassan M Khalil, Mezher M Kadhim, Jalil I Alezzi and Najdat Sh Mahmoud

  Research Article: Clinical Investigation

• Iron deficiency anemia as a risk factor of childhood asthma Maghrib S AlKhateeb, Hassan M Khalil, Mezher M Kadhim, Jalil I Alezzi and Najdat Sh Mahmoud

  Research Article: Clinical Investigation

• Iron deficiency anemia as a risk factor of childhood asthma Maghrib S AlKhateeb, Hassan M Khalil, Mezher M Kadhim, Jalil I Alezzi and Najdat Sh Mahmoud

  Research Article: Clinical Investigation

• Iron deficiency anemia as a risk factor of childhood asthma Maghrib S AlKhateeb, Hassan M Khalil, Mezher M Kadhim, Jalil I Alezzi and Najdat Sh Mahmoud

  Research Article: Clinical Investigation

• Iron deficiency anemia as a risk factor of childhood asthma Maghrib S AlKhateeb, Hassan M Khalil, Mezher M Kadhim, Jalil I Alezzi and Najdat Sh Mahmoud

  Research Article: Clinical Investigation

• Iron deficiency anemia as a risk factor of childhood asthma Maghrib S AlKhateeb, Hassan M Khalil, Mezher M Kadhim, Jalil I Alezzi and Najdat Sh Mahmoud

  Research Article: Clinical Investigation

• Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials Diana I Jalal, Mohammed Sika, Jamie P Dwyer, Ingrid J Chang, Barbara A Greco, Marvin Sinsakul, Simin Goral & Kausik Umanath

  Drug Evaluation: Clinical Investigation

• Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials Diana I Jalal, Mohammed Sika, Jamie P Dwyer, Ingrid J Chang, Barbara A Greco, Marvin Sinsakul, Simin Goral & Kausik Umanath

  Drug Evaluation: Clinical Investigation

• Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials Diana I Jalal, Mohammed Sika, Jamie P Dwyer, Ingrid J Chang, Barbara A Greco, Marvin Sinsakul, Simin Goral & Kausik Umanath

  Drug Evaluation: Clinical Investigation

• Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials Diana I Jalal, Mohammed Sika, Jamie P Dwyer, Ingrid J Chang, Barbara A Greco, Marvin Sinsakul, Simin Goral & Kausik Umanath

  Drug Evaluation: Clinical Investigation

• Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials Diana I Jalal, Mohammed Sika, Jamie P Dwyer, Ingrid J Chang, Barbara A Greco, Marvin Sinsakul, Simin Goral & Kausik Umanath

  Drug Evaluation: Clinical Investigation

• Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials Diana I Jalal, Mohammed Sika, Jamie P Dwyer, Ingrid J Chang, Barbara A Greco, Marvin Sinsakul, Simin Goral & Kausik Umanath

  Drug Evaluation: Clinical Investigation

• Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials Diana I Jalal, Mohammed Sika, Jamie P Dwyer, Ingrid J Chang, Barbara A Greco, Marvin Sinsakul, Simin Goral & Kausik Umanath

  Drug Evaluation: Clinical Investigation

• Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials Diana I Jalal, Mohammed Sika, Jamie P Dwyer, Ingrid J Chang, Barbara A Greco, Marvin Sinsakul, Simin Goral & Kausik Umanath

  Drug Evaluation: Clinical Investigation

• Acknowledgements: Clinical Investigation Vol 3, Iss 2

  Acknowledgements: Clinical Investigation

• Acknowledgements: Clinical Investigation Vol 3, Iss 2

  Acknowledgements: Clinical Investigation

• Acknowledgements: Clinical Investigation Vol 3, Iss 2

  Acknowledgements: Clinical Investigation

• Acknowledgements: Clinical Investigation Vol 3, Iss 2

  Acknowledgements: Clinical Investigation

• Acknowledgements: Clinical Investigation Vol 3, Iss 2

  Acknowledgements: Clinical Investigation

• Acknowledgements: Clinical Investigation Vol 3, Iss 2

  Acknowledgements: Clinical Investigation

• Acknowledgements: Clinical Investigation Vol 3, Iss 2

  Acknowledgements: Clinical Investigation

• Acknowledgements: Clinical Investigation Vol 3, Iss 2

  Acknowledgements: Clinical Investigation

• Challenges in clinical trial design for recurrent glioblastoma Katharine A McNeill, Howard A Fine

  Clinical Trail Methodology: Clinical Investigation

• Challenges in clinical trial design for recurrent glioblastoma Katharine A McNeill, Howard A Fine

  Clinical Trail Methodology: Clinical Investigation

• Challenges in clinical trial design for recurrent glioblastoma Katharine A McNeill, Howard A Fine

  Clinical Trail Methodology: Clinical Investigation

• Challenges in clinical trial design for recurrent glioblastoma Katharine A McNeill, Howard A Fine

  Clinical Trail Methodology: Clinical Investigation

• Challenges in clinical trial design for recurrent glioblastoma Katharine A McNeill, Howard A Fine

  Clinical Trail Methodology: Clinical Investigation

• Challenges in clinical trial design for recurrent glioblastoma Katharine A McNeill, Howard A Fine

  Clinical Trail Methodology: Clinical Investigation

• Challenges in clinical trial design for recurrent glioblastoma Katharine A McNeill, Howard A Fine

  Clinical Trail Methodology: Clinical Investigation

• Challenges in clinical trial design for recurrent glioblastoma Katharine A McNeill, Howard A Fine

  Clinical Trail Methodology: Clinical Investigation

• The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do? Charles H Hennekens, David J Bjorkman

  Commentary: Clinical Investigation

• The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do? Charles H Hennekens, David J Bjorkman

  Commentary: Clinical Investigation

• The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do? Charles H Hennekens, David J Bjorkman

  Commentary: Clinical Investigation

• The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do? Charles H Hennekens, David J Bjorkman

  Commentary: Clinical Investigation

• The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do? Charles H Hennekens, David J Bjorkman

  Commentary: Clinical Investigation

• The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do? Charles H Hennekens, David J Bjorkman

  Commentary: Clinical Investigation

• The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do? Charles H Hennekens, David J Bjorkman

  Commentary: Clinical Investigation

• The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do? Charles H Hennekens, David J Bjorkman

  Commentary: Clinical Investigation

Relevant Topics in Clinical